eXoZymes Inc. (NASDAQ: EXOZ) announced the closing of an underwritten public offering of common stock and warrants, raising approximately $5.95 million in gross proceeds before deducting underwriting discounts, commissions, and estimated offering expenses.

The offering consisted of 330,575 units, including 34,440 units sold through partial exercise of an over-allotment option. Each unit comprised two shares of common stock and one warrant to purchase one additional share. The public offering price was $8.99 per share and $0.02 per warrant.

The warrants become exercisable one year from issuance at an exercise price of $11.24 per share and expire on the five-year anniversary of the issuance date. The warrants are not listed on any national securities exchange. The warrant exercise price may be reset to $0.001 if the company sells additional shares or convertible securities at a per-share price below $8.99 in a public or private offering before June 5, 2027.

The company stated it intends to use net proceeds to support development and commercialization of N-trans-caffeoyltyramine, advance additional product opportunities, fund research and development, and for working capital and general corporate purposes.

MDB Capital acted as sole book-running manager. The securities were offered under a shelf registration statement on Form S-3 declared effective by the U.S. Securities and Exchange Commission on January 23, 2026. A final prospectus supplement was filed with the SEC on June 8, 2026.

eXoZymes, founded in 2019, develops bioengineered enzymes for producing nutraceuticals and medicines from biological feedstocks.